A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated with Miransertib (MK-7075) in Other Studies (MK-7075-006)

Trial Identifier: 7075-006
Sponsor: MSD
Start Date: November 2021
Primary Completion Date: February 2030
Study Completion Date: February 2030
Condition: Genetic Conditions

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary

Trial Locations

Country Location
Australia, New South Wales Newcastle, New South Wales, Australia, 2305
Australia, Queensland Bundaberg, Queensland, Australia, 4670
Brazil, Goias Goiânia, Goias, Brazil, 74605070
Italy, Lazio Roma, Lazio, Italy, 00168
Italy, Roma Rome, Roma, Italy, 00165
United Kingdom, London, City of London, London, City of, United Kingdom, WC1N 3JH
United States, GA Atlanta, GA, United States, 30322
United States, MA Boston, MA, United States, 02115
United States, OH Cincinnati, OH, United States, 45229
United States, TX Houston, TX, United States, 77030
United States, WA Seattle, WA, United States, 98105